Author: Mitchell Gaydash
18 Sep IIVS Partners with SkynFuture to Further In Vitro Research Techniques
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]IIVS is pleased to announce a partnership with SkynFuture, a cosmetics and skincare brand within the UniAsia cosmetics company. IIVS and SkynFuture will collaborate to develop and optimize human-relevant research and testing methods to assess the safety and efficacy of skincare products, and conduct training and other activities to advance non-animal test methods in China.30 Aug Incorporating GIVIMP Recommendations into Method Development, Use, and Transfer
The demand for toxicology data from human-relevant, New Approach Methodologies (NAMs) continues to increase. Fortunately, the scientific community has responded with new tools based on human tissues and cells. The creators of these systems and test methods utilizing them have invested in their development and also in studies designed to demonstrate their relevance, reproducibility, and transferability. Despite these efforts, scientific confidence in these methods at the regulatory level remains comparatively low.24 Aug August 2023 Newsletter
ToxTracker is a unique, stem-cell based assay which takes advantage of a Green Fluorescent Protein (GFP) reporter system to identify hazard and mode-of-action (MOA) of potentially genotoxic materials. On July 20th, IIVS was formally awarded ToxTracker Certification by Toxys, a Dutch Biotechnology company and the...
29 Jul IIVS Acquires Licenses to Work with DEA Schedule I Materials
IIVS is pleased to announce that our lab has acquired the necessary State and Federal licenses required to work with several materials and compounds listed on DEA Schedule 1. These include cannabis and Δ9-THC and related cannabinoids (DEA Drug Codes 7360 & 7370). Our state-of-the...
22 May Multiscale Stiffness of Human Emphysematous Precision-Cut Lung Slices
IIVS is excited to announce a new publication in Science with co-authors at Boston University and Mechanobiologix (Newton, MA, USA)! Abstract: Emphysema is a debilitating disease that remodels the lung leading to reduced tissue stiffness. Thus, understanding emphysema progression requires assessing lung stiffness at both the tissue and alveolar scales.31 Mar IIVS Posters – SOT 2023 Annual Meeting
IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented.14 Mar 62nd Annual Meeting of the Society of Toxicology
IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834. ...
09 Mar IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics...